RAPT Therapeutics, Inc. (RAPT) Research & Development (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Research & Development for 5 consecutive years, with $46.5 million as the latest value for Q4 2024.
- Quarterly Research & Development rose 73.58% to $46.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $107.2 million through Dec 2024, up 6.15% year-over-year, with the annual reading at $107.2 million for FY2024, 6.15% up from the prior year.
- Research & Development hit $46.5 million in Q4 2024 for RAPT Therapeutics, up from $13.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $46.5 million in Q4 2024 to a low of $10.7 million in Q1 2020.
- Historically, Research & Development has averaged $18.9 million across 5 years, with a median of $16.2 million in 2021.
- Biggest YoY gain for Research & Development was 73.58% in 2024; the steepest drop was 50.63% in 2024.
- Year by year, Research & Development stood at $10.9 million in 2020, then soared by 31.14% to $14.3 million in 2021, then soared by 36.05% to $19.5 million in 2022, then surged by 37.58% to $26.8 million in 2023, then surged by 73.58% to $46.5 million in 2024.
- Business Quant data shows Research & Development for RAPT at $46.5 million in Q4 2024, $13.3 million in Q3 2024, and $22.6 million in Q2 2024.